Electromed, Inc. (ELMD) 株式分析

企業概要

Electromed, Inc. is a specialized entity within the healthcare sector, specifically operating in the medical devices industry, where it focuses on the development, manufacturing, marketing, and sales of airway clearance therapy systems. The company's core product line utilizes high frequency chest wall oscillation (HFCWO) therapy to provide pulmonary care solutions for patients both in the United States and internationally. This business model positions Electromed, Inc. as a niche player dedicated to respiratory health technologies rather than broad consumer medical equipment. The company currently maintains a market capitalization of $203.59M and reports trailing twelve-month revenue of $68.86M while employing 177 staff members. These valuation and revenue figures indicate that Electromed, Inc. operates as a mid-sized enterprise with a significant valuation multiple relative to its sales, suggesting that the market assigns a premium to its specialized technology and international distribution capabilities.

財務健全性

Electromed, Inc. reported trailing twelve-month revenue of $68.86M, net income of $8.99M, and EBITDA of $12.88M, highlighting a robust operational efficiency. The gap between revenue and net income reveals a profit margin of 13.1%, while the EBITDA figure of $12.88M against revenue indicates strong top-line profitability before financing and non-cash expenses. The company generated free cash flow of $7.08M, which demonstrates substantial financial flexibility to fund capital expenditures or strategic acquisitions without relying on external financing. Profitability is further evidenced by a gross margin of 78.2%, an operating margin of 19.2%, and a net profit margin of 13.1%, indicating that the company retains high efficiency in production while managing operating costs effectively to deliver returns to shareholders. On the balance sheet, cash holdings of $13.79M significantly exceed total debt of $96,000, supported by a low debt-to-equity ratio of 0.21, which characterizes the company's balance sheet as highly conservative and low-leveraged. Liquidity is exceptionally strong with a current ratio of 4.86, signaling that the company holds ample current assets to cover short-term liabilities many times over. Return on equity stands at 20.2% and return on assets is 13.6%, metrics that reveal management is highly effective at generating returns on the capital invested in the business.

バリュエーション評価

The trailing twelve-month P/E ratio is 23.70, whereas the forward P/E is projected at 40.02, implying that the market expects earnings growth that will significantly narrow this valuation gap over time. The price-to-book ratio of 4.45 suggests that the stock trades at a substantial premium over its book value, reflecting investor confidence in the intangible assets and growth potential of the medical device business. Alternative valuation metrics such as a price-to-sales ratio of 2.96 and an EV/EBITDA of 14.62 provide context that the company is valued at roughly three times its annual sales, which is typical for high-margin medical device firms with specialized products. The stock has experienced volatility within a 52-week range, touching a high of $30.73 and a low of $17.73, meaning the current share price sits dynamically within this historical band relative to recent market movements. A beta of 0.32 indicates that the stock exhibits low volatility relative to the broader market, suggesting that price movements for Electromed, Inc. are less sensitive to general market fluctuations compared to the S&P 500.

Growth & Income

Electromed, Inc. demonstrates dynamic expansion with revenue growth of 16.3% year-over-year and earnings growth of 45.5% year-over-year, indicating that earnings are growing at a significantly faster pace than revenue, which often implies improving operating leverage and cost efficiencies. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to reinvest into research, development, and market expansion rather than distributing cash to shareholders. This reinvestment strategy aligns with the capital-intensive nature of developing and manufacturing airway clearance therapy systems that require continuous technological updates. The overall growth and income profile is defined by strong double-digit revenue expansion and accelerating earnings growth, supported by a capital structure that prioritizes balance sheet strength over current income distributions.